Depakote Monotherapy, Olanzapine Monotherapy, and Combination Therapy of Depakote Plus Olanzapine in Stable Subjects During the Maintenance Phase of Bipolar Illness

PHASE4TerminatedINTERVENTIONAL
Enrollment

180

Participants

Timeline

Start Date

July 31, 2003

Conditions
Bipolar Disorder
Interventions
DRUG

Divalproex Sodium (Delayed-Release Tablets)

DRUG

Divalproex Sodium (Extended-Release Tablets)

DRUG

Olanzapine

Trial Locations (15)

10016

NYU School of Medicine, New York

33161

Segal Institute for Clinical Research, North Miami

33907

Clinical Trial Management, Fort Meyers

39216

University of Mississippi Medical Center, Jackson

40202

University of Louisville Outpatient Psychiatry, Louisville

44106

University Hospital of Cleveland, Cleveland

44124

R. Ranjan, MD & Associates, Inc., Lyndhurst

53295

Zablocki VAMC, Milwaukee

60612

Rush Presbyterian - St. Luke's, Chicago

68131

Creighton University Department of Psychiatry, Omaha

73103

IPS Research, Oklahoma City

89030

Lake Mead Hospital, North Las Vegas

91910

Synergy Clinical Research, Chula Vista

92805

Behavioral and Medical Research, LLC, Anaheim

77555-0197

UTMB Dept. of Psychiatry, Galveston

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Abbott

INDUSTRY

NCT00071253 - Depakote Monotherapy, Olanzapine Monotherapy, and Combination Therapy of Depakote Plus Olanzapine in Stable Subjects During the Maintenance Phase of Bipolar Illness | Biotech Hunter | Biotech Hunter